Physician profile
John M Gooch
NPI 1417935511
$1,909.77
in general payments reported to CMS, 2019-2025
20 companies · $699 in 2025
The $699 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $54.00 · 2021: $135 · 2022: $206 · 2023: $161 · 2024: $530 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,372 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,372.24 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $415.68 | 2024-2025 | Tepezza |
| Regeneron Healthcare Solutions, INC. | $253.41 | 2023-2025 | Eylea Hd, Eylea |
| Novartis Pharmaceuticals Corporation | $250.02 | 2019-2023 | |
| Abbvie INC. | $164.69 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $129.66 | 2019-2025 | |
| Tarsus Pharmaceuticals, INC. | $112.30 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $99.49 | 2024-2025 | Vevye |
| Alcon Vision LLC | $77.55 | 2021-2024 | Rocklatan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $70.10 | 2020-2021 | |
| Astellas Pharma US INC | $58.75 | 2025 | Izervay |
| Genentech USA, INC. | $57.43 | 2025 | Vabysmo |
| Aerie Pharmaceuticals, INC. | $35.54 | 2019-2021 | |
| Horizon Therapeutics Plc | $33.97 | 2023 | Tepezza |
| Djo, LLC | $31.55 | 2023 | Cmf |
| Biotissue Holdings INC. | $29.14 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $19.63 | 2023 | Syfovre |
| Alimera Sciences, INC. | $19.17 | 2024 | Iluvien, Yutiq |
| Kala Pharmaceuticals, INC. | $17.89 | 2019 | |
| Bausch & Lomb Americas INC. | $17.84 | 2023 | Miebo |
| Dompe US, INC. | $15.96 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gooch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.